Viridian Therapeutics, Inc./DE Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount
Viridian Therapeutics, Inc./DE (VRDN) had Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount of $54.90 million as of 2022-12-31, per its 10-K filed 2023-03-09.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized · last filed 2023-03-09
- 2022-12-31: Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount $54.90M.
- 2022-09-30: Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount $53.00M.
- 2022-06-30: Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount $56.90M.
- 2022-03-31: Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount $56.30M.
| Period end | Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount |
|---|---|
| 2022-12-31 | $54.90M 10-K · filed 2023-03-09 |
| 2022-09-30 | $53.00M 10-Q · filed 2022-11-14 |
| 2022-06-30 | $56.90M 10-Q · filed 2022-08-15 |
| 2022-03-31 | $56.30M 10-Q · filed 2022-05-13 |
| 2021-12-31 | $45.10M 10-K · filed 2022-03-11 |
| 2021-09-30 | $42.80M 10-Q · filed 2021-11-05 |
| 2021-06-30 | $36.80M 10-Q · filed 2021-08-12 |
| 2021-03-31 | $48.40M 10-Q · filed 2021-05-07 |
| 2020-12-31 | $9.60M 10-K · filed 2021-03-26 |
| 2020-09-30 | $3.90M 10-Q · filed 2020-11-12 |
| 2020-06-30 | $3.90M 10-Q · filed 2020-08-05 |
| 2020-03-31 | $4.60M 10-Q · filed 2020-05-08 |
| 2019-12-31 | $4.40M 10-K · filed 2020-03-13 |
| 2019-09-30 | $6.40M 10-Q · filed 2019-11-08 |
| 2019-06-30 | $8.60M 10-Q · filed 2019-08-08 |
| 2019-03-31 | $9.60M 10-Q · filed 2019-05-09 |
| 2018-12-31 | $8.30M 10-K · filed 2019-03-14 |
| 2018-09-30 | $9.30M 10-Q · filed 2018-11-07 |
| 2018-06-30 | $10.10M 10-Q · filed 2018-08-08 |
| 2018-03-31 | $10.40M 10-Q · filed 2018-05-09 |
| 2017-12-31 | $7.00M 10-K · filed 2018-03-15 |
| 2017-09-30 | $7.40M 10-Q · filed 2017-11-09 |
| 2017-06-30 | $7.60M 10-Q · filed 2017-08-11 |
| 2017-03-31 | $7.00M 10-Q · filed 2017-05-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |